10X Genomics Inc
$ 25.35
2.22%
15 Apr - close price
- Market Cap 3,168,256,000 USD
- Current Price $ 25.35
- High / Low $ 25.69 / 24.59
- Stock P/E N/A
- Book Value 6.24
- EPS -0.35
- Next Earning Report 2026-05-14
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.06 %
- ROE -0.06 %
- 52 Week High 25.69
- 52 Week Low 7.25
About
10x Genomics, Inc., a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in North America, Europe, the Middle East, Africa, China, and Asia Pacific. The company is headquartered in Pleasanton, California.
Analyst Target Price
$20.62
Quarterly Earnings
| Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-02-12 | 2025-10-28 | 2025-08-07 | 2025-05-08 | 2025-02-12 | 2024-10-29 | 2024-08-08 | 2024-04-30 | 2024-02-15 | 2023-11-02 | 2023-08-03 | 2023-05-03 |
| Reported EPS | 0.0705 | -0.0228 | 0.28 | -0.28 | -0.14 | -0.02 | -0.32 | -0.5 | -0.41 | -0.79 | -0.53 | -0.44 |
| Estimated EPS | -0.2167 | -0.07 | -0.31 | -0.47 | -0.11 | -0.26 | -0.48 | -0.5 | -0.36 | -0.46 | -0.4 | -0.37 |
| Surprise | 0.2872 | 0.0472 | 0.59 | 0.19 | -0.03 | 0.24 | 0.16 | 0 | -0.05 | -0.33 | -0.13 | -0.07 |
| Surprise Percentage | 132.5335% | 67.4286% | 190.3226% | 40.4255% | -27.2727% | 92.3077% | 33.3333% | 0% | -13.8889% | -71.7391% | -32.5% | -18.9189% |
Next Quarterly Earnings
| Mar 2026 | |
|---|---|
| Reported Date | 2026-05-14 |
| Fiscal Date Ending | 2026-03-31 |
| Estimated EPS | -0.25 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: TXG
2026-04-09 09:09:49
This fundamental analysis of 10X Genomics Inc.-Class A (TXG) by ChartMill.com assigns an overall rating of 4 out of 10. While the company exhibits excellent financial health, concerns regarding profitability and its current expensive valuation are highlighted, despite a decent growth rate. The report delves into profitability, health, growth, valuation, and dividend metrics, suggesting a mixed financial outlook for TXG.
2026-04-09 09:09:49
This article provides a stock chart and current price information for 10X Genomics Inc-Class A (NASDAQ:TXG). It shows the current trading price, daily change, and after-hours activity. The page also lists various security sections available, such as technical analysis, fundamental analysis, forecast, and news.
2026-04-03 18:39:39
This page provides live quotes and charts for 10x Genomics Inc. (TXG) stock, showing its current price and daily performance. It notes the absence of analyst ratings and earnings information for the company. The page also features an advertisement for a virtual trading conference and free trade alerts.
2026-04-01 06:09:20
William Blair upgraded 10x Genomics Inc. (NASDAQ: TXG) citing its strong technology and position to benefit from recovering markets and demand for large-scale biological datasets to train AI models. The upgrade is also supported by improving execution and profitability trends, including stabilized single-cell performance and strong fourth-quarter sales. While AI-related revenue is currently small, it is expected to become an important growth area as demand for high-quality biological datasets accelerates.
2026-03-26 15:39:21
Vanguard's recent Schedule 13G/A amendment for 10X Genomics (TXG) indicates that The Vanguard Group now reports zero beneficial ownership of TXG shares. This change is due to an internal realignment effective January 12, 2026, where Vanguard's subsidiaries will now report their holdings separately, as permitted by SEC Release No. 34-39538. This filing represents an administrative adjustment in reporting structure rather than an economic divestiture, and investors are advised to expect separate filings from Vanguard affiliates.
2026-03-26 08:20:00
Serge Saxonov, CEO of 10x Genomics, Inc. (NASDAQ:TXG), sold 15,000 shares of Class A Common Stock for a total of $288,908. These sales occurred on March 23 and 24, 2026, under a pre-arranged Rule 10b5-1 trading plan, following a significant surge in the company's stock price. The transactions leave Saxonov with 1,172,273 directly owned shares and come amidst other company developments, including a new spatial biology initiative and analyst price target increases, though ARK Invest has reduced its holdings.
